Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery

dc.contributor.author
Ramos Izquierdo, Ricard
dc.contributor.author
Macía, Ivan
dc.contributor.author
Navarro Martín, Arturo
dc.contributor.author
Déniz, Carlos
dc.contributor.author
Rivas, Francisco
dc.contributor.author
Ureña Lluveras, Anna
dc.contributor.author
Masuet Aumatell, Cristina
dc.contributor.author
Moreno, Camilo
dc.contributor.author
Nadal, Ernest
dc.contributor.author
Escobar Campuzano, Ignacio
dc.date.issued
2021-04-20T15:29:44Z
dc.date.issued
2021-04-20T15:29:44Z
dc.date.issued
2021-03-02
dc.date.issued
2021-04-20T15:29:44Z
dc.identifier
1471-2466
dc.identifier
https://hdl.handle.net/2445/176526
dc.identifier
711051
dc.identifier
33653309
dc.description.abstract
Background: Tthe aim of this study was to assess the effect of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on overall survival and disease-free survival in patients with lung cancer treated with radical surgery. Methods: we performed a retrospective review of patients with lung cancer who prospectively underwent radical resection between 2004 and 2012. Blood samples were taken as part of the preoperative workup. The inflammatory markers studied were absolute values of lymphocytes, monocytes, neutrophils and platelets, with subsequent calculation of ratios. Median follow-up was 52 months. Results: two hundred and sixty-eight patients underwent surgery, of whom 218 (81.3%) were men. Mean age was 62.9 ± 8.7 years. A lymphocyte-to-monocyte ratio ≥ 2.5 was independently associated with longer disease-free survival (hazard ratio [HR] 0.476 (0.307-0.738), p = 0.001) and longer overall survival (HR, 0.546; 95% CI: 0.352-0.846; p = 0.007), in models adjusted for age, sex, stage, and type of resection. No other systemic inflammatory marker showed a significant association. Conclusion: preoperative LMR is an independent prognostic factor of overall survival and recurrence-free survival in patients with surgically-resected early stage lung cancer.
dc.format
8 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
BioMed Central
dc.relation
Reproducció del document publicat a: https://doi.org/10.1186/s12890-021-01446-1
dc.relation
BMC Pulmonary Medicine, 2021, vol. 21, num. 1, p. 75
dc.relation
https://doi.org/10.1186/s12890-021-01446-1
dc.rights
cc-by (c) Ramos Izquierdo, Ricard et al., 2021
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Càncer de pulmó
dc.subject
Sang
dc.subject
Limfòcits
dc.subject
Lung cancer
dc.subject
Blood
dc.subject
Lymphocytes
dc.title
Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.